ASX RELEASE

22 January 2018

RECEIPT OF SECURITIES IN NOXOPHARM LIMITED (ASX: NOX)

Sydney, 22 January 2018 - Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is pleased to announce that, pursuant to the collaboration with Noxopharm Limited (ASX: NOX) to support future development of NOX66, as announced to ASX on 27 December 2017, the Company has now been issued with the following securities by Noxopharm:

  • • 5,317,123 Fully Paid Ordinary Shares in Noxopharm Limited (ASX: NOX), voluntarily held in escrow until 14 June 2018; and

  • • 3,000,000 Unlisted Options over NOX stock, expiry 18 January 2020, and exercisable @ $0.80 (NOXAT). These options are unable to be exercised prior to 18 July 2018.

The above securities have an estimated market value of approximately AU$6.5 million on the date of issue.

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates and a preclinical discovery program, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial December 2017. Initial data is expected in late calendar 2018, and the study is expected to complete in 2021.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data is expected in the first half of calendar 2018.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

Kazia Therapeutics Limited published this content on 22 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 January 2018 23:14:06 UTC.

Original documenthttps://kza.irmau.com/irm/PDF/1815_1/ReceiptofsecuritiesinNoxopharmLimitedNOX

Public permalinkhttp://www.publicnow.com/view/BF7076A5683DC09780F3CEDD6AC560F39CC70445